Company news

Novavax, Inc. news in 2024

Novavax, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone

December 12, 2024

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

December 9, 2024

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

December 3, 2024

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

November 14, 2024

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

November 11, 2024

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

November 10, 2024

Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

November 3, 2024

Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

October 15, 2024

Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU

October 8, 2024

Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

September 24, 2024

Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.

September 12, 2024

Novavax to Participate in Upcoming September Conferences

September 3, 2024

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

August 29, 2024

Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

August 7, 2024

Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

July 31, 2024

Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

June 23, 2024

Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

June 13, 2024

Novavax to Participate in 2024 Jefferies Global Healthcare Conference

May 29, 2024

Novavax to Participate in BofA Securities 2024 Health Care Conference

May 12, 2024

Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

May 9, 2024

Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024

May 6, 2024

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

March 31, 2024

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference

February 28, 2024

Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

February 27, 2024

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement

February 21, 2024

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

February 19, 2024

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024